U.S. markets closed

Bolt Biotherapeutics, Inc. (BOLT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0400-0.0500 (-4.59%)
At close: 03:59PM EDT
1.0600 +0.02 (+1.92%)
After hours: 05:24PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close1.0900
Bid1.0200 x 1800
Ask1.0900 x 1400
Day's Range1.0200 - 1.1100
52 Week Range1.0100 - 2.0300
Avg. Volume73,682
Market Cap39.469M
Beta (5Y Monthly)0.89
PE Ratio (TTM)N/A
EPS (TTM)-1.9900
Earnings DateNov 08, 2023 - Nov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for BOLT

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Bolt Biotherapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 07/18/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Bolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042

    REDWOOD CITY, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, announced today the issuance of the first and foundational patent covering BDC-3042. The U.S. Patent and Trademark Office (USPTO) issued U.S. Patent 11,753,474 titled “Anti-Dectin-2 Antibodies,” on September 12, 2023. “The issuance of this patent is an important milestone in protecting the comp

  • GlobeNewswire

    Bolt Biotherapeutics to Participate in September Investor Conferences

    REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September: Morgan Stanley 21st Annual Global Healthcare Conference Fireside chat on Tuesday, Sept. 12, at 3:35 p.m. EDT (12:35 p.m. PDT) H.C. Wainwright 25th Annual Global Investment Conference Management will be availabl

  • Simply Wall St.

    Bolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectations

    Bolt Biotherapeutics ( NASDAQ:BOLT ) Second Quarter 2023 Results Key Financial Results Net loss: US$18.1m (loss...